- Prominent psychiatric symptoms masked autism spectrum disorder and OCD, delaying diagnosis by approximately 27 months.
- Risperidone caused significant weight gain and aripiprazole produced nausea, vomiting, dizziness, leading to discontinuation of both FDA-approved agents.
- Off-label low-dose lurasidone 20 mg nightly with sertraline coincided with sustained symptom improvement, but single-case report cannot establish efficacy.
Cureus. 2026 Sep 29;18(9):e117158. doi: 10.7759/cureus.117158. eCollection 2026 Sep.
ABSTRACT
Autism spectrum disorder (ASD) can be difficult to recognize when co-occurring psychiatric symptoms are more clinically prominent, which may delay diagnosis. We report the case of a nine-year-old Latin American boy whose ASD and obsessive-compulsive disorder (OCD) were not diagnosed until approximately 27 months after initial presentation with irritability, mood lability, anxiety, and, subsequently, hallucinatory experiences; these symptoms were initially managed as primary psychiatric conditions. During this interval, fluoxetine was discontinued due to symptom worsening, sertraline produced only partial benefit, and both Food and Drug Administration (FDA)-approved agents for irritability associated with autistic disorder were discontinued because of adverse effects: risperidone due to significant weight gain and aripiprazole due to nausea, vomiting, and dizziness. A detailed neurodevelopmental reassessment subsequently identified longstanding social communication difficulties, rigid routines, sensory sensitivities, and restricted interests, supporting diagnoses of ASD and OCD. Low-dose lurasidone (20 mg nightly) was initiated off-label alongside continued sertraline. Over the following year, the patient demonstrated sustained improvement in irritability, aggression, self-injurious behavior, anxiety, and sleep disturbance. Hallucinatory experiences resolved within approximately three months and did not recur, with no significant adverse effects observed. This case illustrates how more prominent psychiatric symptoms can mask ASD and describes the individualized use of off-label lurasidone after intolerance to approved agents. However, the temporal association with clinical improvement does not establish causality, and findings from a single case cannot demonstrate efficacy.
PMID:42960306 | PMC:PMC13718875 | DOI:10.7759/cureus.117158
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

